116 related articles for article (PubMed ID: 27296769)
1. Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors.
Chatziralli I; Sergentanis T; Zagouri F; Chrysikos D; Ladas I; Zografos GC; Moschos M
Breast J; 2016 Sep; 22(5):561-3. PubMed ID: 27296769
[TBL] [Abstract][Full Text] [Related]
2. Dry eye syndrome in aromatase inhibitor users.
Turaka K; Nottage JM; Hammersmith KM; Nagra PK; Rapuano CJ
Clin Exp Ophthalmol; 2013 Apr; 41(3):239-43. PubMed ID: 22957932
[TBL] [Abstract][Full Text] [Related]
3. Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Moschos MM; Chatziralli IP; Sergentanis T; Zagouri F; Chrysikos D; Ladas I; Zografos G
Cutan Ocul Toxicol; 2016 Mar; 35(1):13-20. PubMed ID: 25597370
[TBL] [Abstract][Full Text] [Related]
4. Dry eyes and AIs: If you don't ask you won't find out.
Inglis H; Boyle FM; Friedlander ML; Watson SL
Breast; 2015 Dec; 24(6):694-8. PubMed ID: 26422124
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
6. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
7. Vascular effects of aromatase inhibitors: data from clinical trials.
Howell A; Cuzick J
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
[TBL] [Abstract][Full Text] [Related]
8. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
9. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
10. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Crew KD; Greenlee H; Capodice J; Raptis G; Brafman L; Fuentes D; Sierra A; Hershman DL
J Clin Oncol; 2007 Sep; 25(25):3877-83. PubMed ID: 17761973
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
13. Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer.
Scarpa R; Atteno M; Peluso R; Costa L; Padula S; Di Minno D; Caso F; Iervolino S; Vitiello M; Del Puente A
J Clin Rheumatol; 2011 Jun; 17(4):169-72. PubMed ID: 21617557
[TBL] [Abstract][Full Text] [Related]
14. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
[TBL] [Abstract][Full Text] [Related]
15. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Ingle JN
Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Dent SF; Gaspo R; Kissner M; Pritchard KI
Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
18. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
Moegele M; Buchholz S; Seitz S; Ortmann O
Arch Gynecol Obstet; 2012 May; 285(5):1397-402. PubMed ID: 22212649
[TBL] [Abstract][Full Text] [Related]
19. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
20. Association of estrogen receptor alpha (ERĪ±) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors.
Koukouras D; Marioli DJ; Papadopoulos K; Adonakis GL; Armeni AK; Georgopoulos NA; Decavalas G
Gynecol Endocrinol; 2012 Nov; 28(11):859-62. PubMed ID: 22799738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
